- Home
- HTBK vs PGEN Comparison
HTBK vs PGEN Comparison
Compare HTBK & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBK
- PGEN
- Stock Information
- Founded
- HTBK 1997
- PGEN 1998
- Country
- HTBK United States
- PGEN United States
- Employees
- HTBK N/A
- PGEN N/A
- Industry
- HTBK Major Banks
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- HTBK Finance
- PGEN Health Care
- Exchange
- HTBK Nasdaq
- PGEN Nasdaq
- Market Cap
- HTBK 566.4M
- PGEN 577.0M
- IPO Year
- HTBK 1998
- PGEN N/A
- Fundamental
- Price
- HTBK $10.50
- PGEN $1.91
- Analyst Decision
- HTBK Buy
- PGEN Buy
- Analyst Count
- HTBK 3
- PGEN 5
- Target Price
- HTBK $11.50
- PGEN $7.00
- AVG Volume (30 Days)
- HTBK 450.4K
- PGEN 2.0M
- Earning Date
- HTBK 01-23-2025
- PGEN 03-18-2025
- Dividend Yield
- HTBK 4.80%
- PGEN N/A
- EPS Growth
- HTBK N/A
- PGEN N/A
- EPS
- HTBK 0.66
- PGEN N/A
- Revenue
- HTBK $170,257,000.00
- PGEN $3,963,000.00
- Revenue This Year
- HTBK N/A
- PGEN N/A
- Revenue Next Year
- HTBK $5.03
- PGEN $402.12
- P/E Ratio
- HTBK $16.29
- PGEN N/A
- Revenue Growth
- HTBK N/A
- PGEN N/A
- 52 Week Low
- HTBK $7.66
- PGEN $0.65
- 52 Week High
- HTBK $11.27
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- HTBK 62.99
- PGEN 68.55
- Support Level
- HTBK $10.30
- PGEN $1.63
- Resistance Level
- HTBK $10.79
- PGEN $2.17
- Average True Range (ATR)
- HTBK 0.34
- PGEN 0.18
- MACD
- HTBK 0.05
- PGEN 0.02
- Stochastic Oscillator
- HTBK 76.16
- PGEN 71.74
About HTBK Heritage Commerce Corp
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two segments, namely Banking and Factoring. The bank generates its revenue from the Banking segment.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.